New Jersey
Prescription drug spending and prescribing in New Jersey, from Medicare Part D and Medicaid, with the life-science companies raising money there and state attorney general health-care antitrust cases. Compare every state.
In 2024, Medicare Part D plans paid $8.0B for prescriptions written in New Jersey, the 11th most of 52 states and territories, and 2.4% of its claims were opioids against 3.5% nationally.
- Medicare Part D, 2024: $8.0B
- Medicaid drugs, 2025: $2.0B
- Opioid share of claims: 2.4%
- Life-science raises, 2 years: $375M
How It Prescribes
Medicare Part D, 2024, by the prescriber's state| Share of Part D claims | New Jersey | United States | Difference |
|---|---|---|---|
| Opioids | 2.4% | 3.5% | -31% |
| Antibiotics | 4.6% | 4.4% | +3% |
| Antipsychotics | 1.8% | 1.7% | +4% |
Most Distinctive Drugs
Prescribed most out of line with the rest of the country: the drug's share of New Jersey's claims against its share nationally| Drug | Against national rate | Claims |
|---|---|---|
| Repaglinide | 5.3× | 47,256 |
| Pitavastatin Calcium | 2.7× | 20,339 |
| Collagenase Clostridium Hist. | 2.6× | 16,756 |
| Ammonium Lactate | 2.6× | 79,627 |
| Silodosin | 2.5× | 18,750 |
| Ramipril | 2.4× | 91,732 |
| Ezetimibe/Simvastatin | 2.4× | 16,009 |
| Amlodipine Bes/Olmesartan Med | 2.4× | 20,534 |
| Cefuroxime Axetil | 2.3× | 65,238 |
| Tobramycin/Dexamethasone | 2.2× | 32,252 |
Biggest Medicaid Drugs
What New Jersey's Medicaid program paid pharmacies, before rebates; see every drugLife-Science Fundraising
75 Form D raises by companies based in New Jersey in the last two years; the 10 largest. See all raises- Aadi Bioscience, Inc.$100M · Biotech · Mar 18, 2025
- Character Biosciences, Inc.$48M · Biotech · May 12, 2025
- Thrombolex, Inc.$33M · Other health care · Mar 12, 2026
- Vinci Pharmaceuticals, Inc.$20M · Other health care · Jan 26, 2026
- AR CPT Holdings Inc.$20M · Other health care · Feb 24, 2025
- Grace Therapeutics, Inc.$15M · Biotech · Feb 25, 2025
- Grace Therapeutics, Inc.$10M · Pharma · Aug 11, 2026
- Character Biosciences, Inc.$9M · Biotech · Sep 17, 2025
- Ensho Therapeutics, Inc.$7M · Biotech · Oct 15, 2026
- Orcosa Inc.$7M · Biotech · Jan 7, 2025
State Attorney General Health-Care Cases
Antitrust cases New Jersey joined, newest first; see every case- United States and Plaintiff States v. UnitedHealth et al. (D. Md. 1:24-cv-03267-JKB)2025 · Final judgment
- Connecticut, et al. v. Sandoz, et al., Case No. 20-cv-3539 (E.D. Pa. June 10, 2020), MDL 2724 (E.D. Pa.)2020 · Pending
- Connecticut et al. v. Teva Pharmaceuticals USA, Inc. et al., No. 2:19-cv-02407, (E.D. Pa. filed in MDL 05/30/2019)2019 · Pending
- New York et al. v. Cephalon, No. 2:16-cv-04234 (E.D. Pa. Aug. 4, 2016)2016 · Settled
- Maryland et al. v. Perrigo Company, No. 1:04CV01398 (D.D.C. Aug. 17, 2004)2004 · Settled
- Texas et al. v. Organon (Remeron), No. 04-5126 (D.N.J. 2004)2004 · Settled
- In re Cardizem CD Antitrust Litigation 99-MD-1278 (E.D. Mich. Jan. 29, 2003), 332 F.3d 896 (6th Cir. 2003)2003 · Settled
- Ohio, et al, v. Bristol-Myers Squibb Co., et al.(D.D.C. 2002); see also In re Buspirone Antitrust Litigation,Case No. 01 CV 11401, MDL…2002 · Settled
- In re Clozapine Antitrust Litigation, MDL No. 874 (N.D. Ill. 1991)1991 · Settled
- New Jersey v. Nurses Private Duty Registry, Inc., 1977-2 Trade Cas. (CCH) 61,809 (N.J. Super. Ct. 1977)1977 · Settled
Other States
Alabama · Alaska · Arizona · Arkansas · California · Colorado · Connecticut · Delaware · District of Columbia · Florida · Georgia · Hawaii · Idaho · Illinois · Indiana · Iowa · Kansas · Kentucky · Louisiana · Maine · Maryland · Massachusetts · Michigan · Minnesota · Mississippi · Missouri · Montana · Nebraska · Nevada · New Hampshire · New Mexico · New York · North Carolina · North Dakota · Ohio · Oklahoma · Oregon · Pennsylvania · Puerto Rico · Rhode Island · South Carolina · South Dakota · Tennessee · Texas · Utah · Vermont · Virginia · Washington · West Virginia · Wisconsin · Wyoming
Part D is by the prescriber's state, Medicaid by the paying state program, and Form D by the issuer's stated address. Amounts are before manufacturer rebates. Refreshed weekly. CMS Medicare Part D Prescribers by Geography; CMS State Drug Utilization Data; SEC Form D; NAAG